United Therapeutics Corp., of Silver Spring, Md., said it completed enrollment in its FREEDOM-M registration trial testing a sustained-release, oral formulation of treprostinil diethanolamine in pulmonary arterial hypertension (PAH) patients not receiving any other approved PAH therapy. The study enrolled 349 patients, above the target enrollment of 315.